Download PDFPDF
Non-commercial clinical trials of a medicinal product: can they survive the current process of research approvals in the UK?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Response to Ethical Review of Non-commercial Clinical Trials
    • Nat MJ Wright, Clinical Director
    • Other Contributors:
      • Clive E. Adams, Laura Sheard

    Dear Editor,

    In response to the electronic letter by Peter Heasman “Ethical Review of Non-commercial Clinical Trials”, the LEEDS project team must emphasise that we do not wish to either overtly or covertly criticise activity of MREC individuals. We realise that many active researchers sit alongside non-researchers on MREC committees and surely our common goal is to foster a culture of research development and in...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Ethical review of non-commercial clinical trials

    Dear Editor,

    Sheard et al. are right to raise awareness regarding the practicality of the ‘approvals process’ for non-commercial clinical trials and the duplicative application process that often involves research governance, ethics, the research sponsor and, for trials involving medicinal products, the MHRA. This can indeed be a time-consuming and often frustrating process. I would, however, like to respond to a num...

    Show More
    Conflict of Interest:
    None declared.